1. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
- Author
-
Ercilla Liceaga M, Andueza Granados K, Fernández González I, and Barcia Romero MJ
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacology, Arsenic Trioxide, Arsenicals administration & dosage, Arsenicals adverse effects, Arsenicals pharmacology, Clinical Trials as Topic, Humans, Oxides administration & dosage, Oxides adverse effects, Oxides pharmacology, Antineoplastic Agents therapeutic use, Arsenicals therapeutic use, Leukemia, Promyelocytic, Acute drug therapy, Oxides therapeutic use
- Abstract
Arsenic trioxide has drawn renewed interest in onco-haematological therapy. Based on a number of studies quoted in this paper, it has been approved by FDA and EMEA for remission induction and consolidation therapy of acute promyelocytic leukaemia in patients refractory to treatment using trans-retinoic acid and anthracyclines. In addition to briefly discuss available therapeutic resources against this disease, this review attempts to provide an in-depth view of this drugâs characteristics and efficacy, as shown in several studies.
- Published
- 2003